Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Bydureon’s U.S. Approval, Amylin Extends Exenatide Franchise

This article was originally published in The Pink Sheet Daily

Executive Summary

Twice delayed by “complete response” letters, the drug’s approval gives Amylin a once-weekly GLP-1 analog, the longest-acting drug in its class.


Related Content

On The Wings Of Lantus: Sanofi Sees Clearer Skies Ahead In Diabetes
Bristol And AstraZeneca Make A Splash In Diabetes With Joint Purchase Of Amylin
PhaseBio Diabetes Program Reaches Inflection Point With Series B Add-On
Icahn Turns Up The Heat On Amylin, Urges Board To Sell
Weeks After Bydureon Launch, Amylin Looks Like A Takeout Target
Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation
Caught Between Two Partners: Amylin Seeks To Block Lilly's Byetta Sales Force From Marketing Tradjenta
Amylin Plans Cardiac Safety Study By The Book After Bydureon Rejection
FDA's "Complete Response" Letter For Byetta LAR Isn't Too Onerous, Amylin Says
FDA Clears Victoza, But Warnings And More Studies Pose Hurdles


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts